tiprankstipranks
Advertisement
Advertisement
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
PremiumRatingsMaze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
2M ago
Maze Therapeutics reports Q1 EPS (45c), consensus (63c)
Premium
The Fly
Maze Therapeutics reports Q1 EPS (45c), consensus (63c)
2M ago
Maze Therapeutics prices $150 million equity offering
Premium
Company Announcements
Maze Therapeutics prices $150 million equity offering
3M ago
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
PremiumRatingsEncouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
4M ago
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
Premium
The Fly
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
4M ago
Maze Therapeutics falls -29.8%
Premium
The Fly
Maze Therapeutics falls -29.8%
4M ago
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
PremiumThe FlyMaze Therapeutics reports Q4 EPS (65c), consensus (78c)
4M ago
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
Premium
The Fly
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
4M ago
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
Premium
The Fly
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100